At Cook Children's, you'll find the best pediatric doctors in North Texas. Our professionals put the health and well-being of your child first and foremost.
Find a Pediatrician Find a Specialist
Cook Children's provides a complete network of care to children across the state of Texas.
Pediatric Offices Specialty Clinics
Medical Center Urgent Care Clinics
Surgery Centers Pharmacy
Home Health Virtual Health
Emergency Rooms NEW Locations
Looking for a pediatric specialty clinic? Cook Children's has more than 60 locations across North Texas, because even when your child's diagnosis is complicated, finding the right care should be simple.
Specialty Clinics Specialty Referrals
Cook Children's is pleased to be participating with Children's Oncology Group (COG) and National Cancer Institute (NCI) in ANBL 1531, a partially randomized phase III trial that studies I-131-MIBG or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as I-131-MIBG, are designed to carry radiation directly to tumor cells without harming normal ones. Crizotinib may stop the growth of ALK aberrant tumor cells by blocking some of the enzymes needed for cell growth. Giving I-131-MIBG or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma, giving more hope to patients and their families.
Upfront therapy for neuroblastoma patients: ANBL1531: A Phase 3 Study of I-131-Metaiodobenzylguanidine (I-131-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL).
Participants in this trial are newly diagnosed high-risk neuroblastoma or ganglioneuroblastoma patients ages 1 to 30 years.
I-MIBG has the potential to improve event free survival (EFS) rate in children with chemoresistant disease. Initial trials indicate intensification of consolidation therapy (sequential high dose chemotherapy) with autologous stem cell rescue improves outcomes. In this trial, we will study if giving MIBG earlier in therapy is advantageous to neuroblastoma patients.
In this trial there are two types of patient groups, or ARMS: randomized and assigned.
As key collaborators with the nation's leading pediatric research organizations, we offer the best available treatments and actively contribute to the search for a cure. Our ultimate goal is to erase kid cancer.
M. Meaghan Granger, M.D., specializes in treating Neuroblastoma patients and is very active in research. Get to know Dr. Granger and see what research programs she is currently active in. Get to know Dr. Granger and see what research programs she is currently active in.
Contact Cook Children's Neuroblastoma Program Clinical Coordinator at